Nihar R. Desai, MD, MPH


Clinical Evidence Supporting Cardiovascular and Renal Indications in SGLT2 Inhibitors and GLP-1 Receptor Agonists

August 20, 2021

Om P. Ganda, MD, provides an overview of the clinical trials supporting the use of SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular and renal indications, and Jeffrey Turner, MD, comments on the kidney disease outcome measures of these trials.